-+ 0.00%
-+ 0.00%
-+ 0.00%
Dicot Pharma Kicks off Erectile Dysfunction Drug Candidate Trial
Share
Listen to the news
01:22 AM EST, 11/18/2026 (MT Newswires) -- Dicot Pharma (DICOT.ST) launched a phase 2b trial of its erectile dysfunction drug candidate, LIB-01, the Sweden-listed pharmaceutical company said Wednesday. The first part of the study, expected to be completed in the first quarter of 2027, will determine the highest dose to be evaluated in the second part of the study. The trial will assess LIB-01's effects following repeated monthly dosing, with the primary efficacy endpoint being the change from baseline in the International Index of Erectile Function erectile function domain score at week 12. The results will help guide dose selection ahead of phase 3.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending